Enterprise value to EBITDA forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS
This article provides financial data for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its enterprise value to EBITDA forward metric. It appears to be a stub or data-focused page from TradingView, indicating that the market was closed at the time of access.
Insider reports 400-share purchase and 17,000 RSUs | XERS SEC Filing - Form 144
A recent SEC Form 144 filing for Xeris Biopharma Holdings, Inc. (XERS) reported insider transactions, including an open-market purchase of 400 common shares on May 17, 2017, and an issuance of 17,000 restricted stock units (RSUs) on December 28, 2017. The filing's header date is July 6, 2026, clarifying that it is a disclosure of past transactions rather than new ones. An equity compensation lawyer noted these are routine disclosure items.
Enterprise value to EBIT forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS
This article provides financial data for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its enterprise value to EBIT forward. It indicates market details such as "Market closed" and "No trades," suggesting the data presented might be static or from a non-trading period.
Price to book forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS
This article provides the "Price to book forward" for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS). It is a financial data point displayed within the TradingView platform, showing the value and change percentage for a specific period. The content is primarily a presentation of this financial metric.
Price to book forward of Xeris Biopharma Holdings, Inc. – LSE:0A8E
This article provides limited financial data for Xeris Biopharma Holdings, Inc. (LSE:0A8E), specifically its "Price to book forward" metric. The content primarily focuses on the company's financial overview within the TradingView platform and includes extensive navigation and copyright information.
Price to sales forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS
This article provides financial information for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its forward price to sales ratio. The content is presented within the TradingView platform, offering various market analysis tools and data provided by ICE Data Services and FactSet.
If You Invested $1,000 in Xeris Biopharma Holdings (XERS)
This article analyzes the historical performance of investing $1,000 in Xeris Biopharma Holdings (XERS) over various periods, showing significant returns for investments made one and five years ago, but a loss for investments since its 2018 trading start. It details the company's biopharmaceutical focus, its key commercial products (Recorlev, Gvoke, Keveyis), and its pipeline, including XP-8121. The article also provides a company overview with financial metrics and compares XERS's yearly returns against the S&P 500.
Xeris Biopharma Holdings (XERS) Patent Win Puts Its Valuation Back In Focus
Xeris Biopharma Holdings (XERS) has garnered attention due to a patent win for its Keveyis product, potentially extending protection until 2039, and recent board and leadership changes. Despite being considered 25.7% undervalued at its current price of $8.28 against a fair value of $11.14, the company's high P/E ratio of 119x compared to a fair ratio of 35.4x suggests potential valuation risk if growth slows. Analysts project significant revenue growth of 21.5% annually and a rise in profit margins from -13.0% to 19.2% over the next three years.
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Xeris Biopharma Holdings, Inc. announced that its Compensation Committee granted non-qualified stock options and restricted stock units for an aggregate of 221,323 shares to 47 new employees. These inducement grants are made under Nasdaq Listing Rule 5635(c)(4) and are intended to attract new talent to the company. The awards will vest over three years, contingent on continued employment.
Beth Hecht Sells 16,666 Shares of Xeris Biopharma Holdings Inc (XERS)
Beth Hecht, an insider at Xeris Biopharma Holdings Inc (XERS), sold 16,666 shares of the company on July 1, 2026, bringing her total ownership to 1,161,128 shares. This sale contributes to a pattern of 24 insider sells and no buys over the past year. The stock, trading at $8.03, appears significantly overvalued with a price-to-GF-Value ratio of 1.56, based on GuruFocus's intrinsic value estimate.
Form 4 Xeris Pharmaceuticals Inc For: 2 July By Investing.com
The article reports on a Form 4 filing for Xeris Pharmaceuticals Inc. on July 2. Form 4 filings detail changes in beneficial ownership of company securities by insiders. The article also provides various financial market data and news headlines.
Xeris Biopharma (XERS) director Nerissa Kreher listed as reporting person on Form 3
Xeris Biopharma Holdings, Inc. director Nerissa Kreher has been listed as a reporting person on a recently filed Form 3. This initial statement of beneficial ownership indicates no reported buying, selling, acquiring, disposing, or other share transactions, with all transaction counts and share amounts listed as zero. The filing clarifies that Ms. Kreher is a director but not a ten percent owner and holds no beneficially owned securities or derivative positions according to this Form 3.
Planned sale: Xeris Biopharma (XERS) officer trades 16,666 shares
Xeris Biopharma Holdings, Inc. officer Beth Hecht reported selling 16,666 shares of common stock at a weighted average price of $8.0319 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. After the sale, Hecht retains a substantial equity position with 1,161,128 shares, including recent acquisitions from the company's Employee Stock Purchase Plan.
Director at Xeris Biopharma (NASDAQ: XERS) receives stock and options grants
Xeris Biopharma director Nerissa Kreher received equity-based compensation including 33,582 restricted stock units and stock options for 37,910 shares with an exercise price of $8.00. Both grants vest over three years, contingent on her continued service on the board. This Form 4 filing reports compensation awards, not open-market transactions, and the options expire on July 1, 2036.
Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Xeris Biopharma Holdings, Inc. announced that its Compensation Committee granted restricted stock units for 221,323 shares of common stock to 47 new employees on July 1, 2026. These grants were made under Xeris' Inducement Equity Plan, exclusively for new hires to incentivize employment, in accordance with NASDAQ Listing Rules. The restricted stock units will vest over three years, contingent on continued employment.
Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Xeris Pharmaceuticals, Inc. announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). These grants were made to newly hired employees, as an inducement material to their employment. The compensation committee of Xeris' board of directors approved these grants.
[144] Xeris Biopharma Holdings, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Xeris Biopharma Holdings, Inc. (XERS), indicating an intent to sell 120,000 shares of common stock with an aggregate market value of $950,400.00. The securities were acquired on January 29, 2024, as Restricted Stock Units from the Issuer and are intended to be sold on NASDAQ via Morgan Stanley Smith Barney LLC. The filing was accepted by the SEC on July 1, 2026, at 04:21 PM.
XERS - Xeris Biopharma Holdings Inc Options
This page provides an extensive overview of Xeris Biopharma Holdings Inc (XERS), including its last closing price, financial metrics, valuation ratios, and performance indicators. It also lists key statistics like market capitalization, income, sales, EPS, insider ownership, institutional ownership, and various growth rates. The data covers a range of information pertinent to potential investors and analysts.
Xeris Biopharma (NASDAQ: XERS) adds Nerissa Kreher and reshapes board
Xeris Biopharma has announced significant changes to its Board of Directors, effective July 1, 2026. The company expanded its board from seven to eight members with the appointment of Dr. Nerissa Kreher as a Class III director. Additionally, CEO John Shannon has been named Chairperson of the Board, and Marla S. Persky will transition to Lead Independent Director, consolidating leadership while maintaining independent oversight.
Xeris CEO picks up chairman role at fast-growing biopharma
John Shannon, the CEO of Xeris Biopharma, has been appointed chairman of the company. This move sees him taking on an expanded leadership role at the fast-growing biopharma firm. The article, however, does not provide further details on the implications of this new appointment or the company's growth trajectory.
Xeris Biopharma Holdings, Inc. Announces Board Changes, Effective July 1, 2026
Xeris Biopharma Holdings, Inc. announced significant changes to its Board of Directors, effective July 1, 2026. John Shannon, the current Chief Executive Officer, will also assume the role of Chair of the Board, succeeding Marla Persky who remains as Lead Independent Director. Additionally, Dr. Nerissa Kreher was appointed to the Board, expanding its membership to eight.
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?
Xeris Biopharma Holdings, Inc. (XERS) has secured a patent allowance for its Keveyis product, which is expected to extend intellectual property protection until 2039. Concurrently, the company is retiring approximately $23 million in convertible senior notes through a combination of cash and stock issuance, aiming to reduce outstanding debt to $10.5 million. These strategic moves bolster Xeris's commercial position as a biopharmaceutical company focusing on endocrine and neurological disorders.
Xeris Announces Updates to Its Board of Directors
Xeris Biopharma Holdings, Inc. announced updates to its Board of Directors, effective July 1, 2026. John Shannon, the current CEO, has also been appointed Chair of the Board, succeeding Marla Persky, who will transition to Lead Independent Director. Additionally, Dr. Nerissa Kreher, an accomplished physician-scientist and biotech executive, has been appointed to the Board, expanding it to eight members.
Xeris Announces Updates to Its Board of Directors
Xeris Biopharma Holdings, Inc. announced updates to its Board of Directors, appointing CEO John Shannon as Chair and transitioning Marla Persky to Lead Independent Director, both effective July 1, 2026. The company also appointed Nerissa Kreher, M.D., to the Board, expanding it to eight members. These changes reflect confidence in Shannon's leadership and aim to leverage Kreher's expertise in rare disease therapies.
Xeris Biopharma Holdings, Inc. Actuals & Estimates (NASDAQ:XERS)
This article provides an overview of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), including its current stock price, historical performance, analyst forecasts, and recent financial results. It highlights that the stock has seen significant increases over the past year and that analysts have a positive outlook with a maximum price target of $18.00. The company's market capitalization, upcoming earnings date, and recent revenue and net income figures are also detailed.
XERS Forecast — Price Target — Prediction for 2027
This article provides a forecast for Xeris Biopharma Holdings, Inc. (XERS) stock, including analyst price targets, historical stock performance, and financial data. It highlights the company's current stock price, market capitalization, volatility, and details on its past earnings and revenue reports. The article also touches on future earnings expectations and provides guidance on how to interpret technical analysis for XERS stock.
0A8E Forecast — Price Target — Prediction for 2027
This article provides an in-depth financial analysis and forecast for Xeris Biopharma Holdings, Inc. (0A8E) stock. It includes analyst price targets, past and future earnings estimates, revenue expectations, and key financial metrics like EBITDA and market capitalization. The article also addresses frequently asked questions about the company's stock performance, volatility, and dividend policy.
Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Xeris Biopharma Holdings Inc (XERS), detailing its current price momentum score of 9.43 within the Pharmaceuticals industry. It identifies resistance and support levels at $7.40 and $6.10, respectively, and offers a summary of various technical indicators and moving averages, largely indicating a "Buy" signal based on moving averages.
Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Xeris Biopharma Holdings Inc (XERS) has an earnings forecast score of 8.57, ranking 28th in the Pharmaceuticals industry. Analysts have a consensus "Buy" rating with an average target price of $10.00, suggesting a potential upside of 64.04%. The company's expected revenue for the next quarter is $90.29 million.
Xeris Biopharma Holdings Inc (XERS) Institutional Confidence
Xeris Biopharma Holdings Inc (XERS) has an institutional shareholding score of 5.00, placing it 73rd out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 57.26%, which is a 4.21% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, with other significant holders including BlackRock, D. E. Shaw & Co., and Geode Capital Management.
Xeris Biopharma Holdings Inc (XERS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Xeris Biopharma Holdings Inc (XERS), detailing its business segments and the proportion of revenue contributed by each product. The data, updated on January 6th, shows Recorlev as the top revenue generator, followed by Gvoke and Keveyis, with a small portion from royalty and other revenue. The report also highlights the company's market capitalization and P/E TTM ratio.
Xeris Biopharma Holdings Inc (XERS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend and stock split history for Xeris Biopharma Holdings Inc (XERS). It states that the company has distributed $0.00 in dividends over the past five years and reports no data for historical stock splits. The page also includes current stock information such as market cap and P/E ratio.
Xeris Pharmaceuticals, Inc. (XERS) stock price, news, quote and history
Xeris Pharmaceuticals, Inc. (XERS) stock closed at $6.79, down 2.02%, with a market capitalization of $1.172 billion. The biopharmaceutical company develops therapies for chronic endocrine and neurological diseases, including Gvoke, Keveyis, and Recorlev. Analysts have an average target price of $11.29 for XERS, with a "Buy" recommendation.
Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma
Jim Cramer endorsed a caller's speculative investment in Xeris Biopharma, emphasizing that such targeted speculation is healthy if kept limited. Xeris Biopharma (NASDAQ: XERS) develops therapies for chronic endocrine and neurological diseases, including a phase 3 trial for a hypothyroidism treatment. The article also contrasts speculative stock picking with promising AI stocks, suggesting the latter offers higher returns.
Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma
Jim Cramer endorsed a caller's speculative investment in Xeris Biopharma (NASDAQ:XERS), emphasizing that one such speculative play is sufficient. Xeris Biopharma develops therapies for chronic endocrine and neurological diseases, including treatments for hypoglycemia and hypercortisolemia, and has a phase 3 clinical trial underway for a hypothyroidism treatment. While acknowledging XERS's potential, the article suggests that certain AI stocks may offer greater upside with less risk.
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS
Xeris Biopharma has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering its KEVEYIS® (dichlorphenamide) product, an FDA-approved treatment for primary periodic paralysis. This patent is expected to provide intellectual property protection for KEVEYIS through 2039. The company emphasizes its commitment to the primary periodic paralysis community by strengthening the intellectual property of this important therapy.
Jim Cramer Discussed 15 Stocks, Including Broadcom, Netflix, and His Skepticism Toward Tech Stocks
Jim Cramer expressed skepticism towards tech stocks and discussed several companies including Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), which he endorsed as a suitable speculative investment. He advised a caller to limit speculative investments to just one within their portfolio. Xeris Biopharma is developing therapies for chronic endocrine and neurological diseases, with one drug currently in phase 3 clinical trials.
Jim Cramer Discussed 15 Stocks, Including Broadcom, Netflix, and His Skepticism Toward Tech Stocks
Jim Cramer shared his views on 15 stocks, including Broadcom and Netflix, emphasizing his skepticism towards tech stocks leading the market. He advised a caller to have only one speculative investment, commenting on Xeris Biopharma Holdings (NASDAQ: XERS) as a suitable option for such a purpose. Cramer highlighted that Xeris focuses on developing therapies for chronic endocrine and neurological diseases, including a once-weekly subcutaneous injection for hypothyroidism currently in a phase 3 clinical trial.
Xeris Biopharma Announces Private Exchange of Convertible Notes
Xeris Biopharma announced private exchange agreements with holders of its 8.00% Convertible Senior Notes due 2028. This transaction will retire approximately $23 million in debt, saving about $2 million in annual interest. Consideration includes $23 million in cash and shares of common stock, expected to be around 4.6 million shares based on a trailing average price.
Xeris Biopharma to retire $23 million in convertible notes
Xeris Biopharma Holdings, Inc. announced its plan to retire approximately $23 million in 8.00% Convertible Senior Notes due 2028 through exchange agreements. The company will pay the principal in cash and issue approximately 4.6 million shares of common stock, based on a recent closing price. This move is expected to save $2 million in annual interest, leaving $10.5 million in outstanding notes and a total debt of about $259 million.
Xeris Biopharma (NASDAQ: XERS) to retire $23M of 8% notes in cash-and-stock deal
Xeris Biopharma Holdings has entered into agreements to retire approximately $23 million of its 8.00% Convertible Senior Notes due 2028 through a cash-and-stock exchange. The company will use $23 million in cash and issue new common shares, the number of which will be determined by the 21-day volume-weighted average price starting June 11, 2026. This move is expected to reduce annual interest expenses by about $2 million, leaving $10.5 million of the notes outstanding.
Xeris Biopharma Announces Private Exchange of Convertible Notes
Xeris Biopharma Holdings, Inc. announced a private exchange of approximately $23 million of its 8.00% Convertible Senior Notes due 2028. This exchange is expected to eliminate about $23 million in debt and result in approximately $2 million in annual interest savings. The consideration for the exchange will consist of cash and shares of Xeris's common stock, with about 4.6 million shares expected to be issued.
Xeris Biopharma Announces Private Exchange of Convertible Notes
Xeris Biopharma has announced a private exchange of its 8.00% Convertible Senior Notes due 2028 with certain holders. This transaction will eliminate approximately $23 million of debt, resulting in an annual interest savings of about $2 million. The consideration for the exchange will consist of cash and common stock, with an estimated 4.6 million shares to be issued.
Xeris Biopharma director Marla Persky sells $91,432 in shares
Marla Persky, a director at Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), sold 15,500 shares totaling $91,432 on June 3, 2026, under a pre-arranged trading plan. Despite this sale, Persky acquired 24,193 shares via an RSU grant and 32,996 stock options the following day, demonstrating continued involvement with the company. The article notes that Xeris Biopharma's stock appears undervalued according to InvestingPro analysis, with strong fundamentals including 41% revenue growth and an 86% gross profit margin.
Xeris Biopharma director John Johnson sells $91,422 in shares
Xeris Biopharma director John Johnson sold 15,000 shares worth $91,422 from a Rule 10b5-1 trading plan. On the same day, he acquired 24,193 shares through a restricted stock unit grant and 32,996 stock options. The company recently reported strong first-quarter 2026 financial results, with a 38% increase in revenue and exceeding EPS expectations, and its stock is considered undervalued by InvestingPro.
Xeris Biopharma director John Johnson sells $91,422 in shares By Investing.com
John Johnson, a director at Xeris Biopharma Holdings, Inc. (XERS), sold 15,000 shares worth $91,422 on June 4, 2026, under a Rule 10b5-1 trading plan. Despite this sale, he acquired 24,193 shares through a restricted stock unit grant and 32,996 stock options on the same day, increasing his overall direct ownership in the company. Xeris Biopharma recently reported strong financial results for Q1 2026 with a 38% revenue increase and exceeded EPS expectations, indicating a robust performance.
Xeris Biopharma director Marla Persky sells $91,432 in shares
Marla Persky, a director at Xeris Biopharma Holdings, Inc., sold 15,500 shares for $91,432 on June 3, 2026, under a pre-arranged trading plan. The day after the sale, she acquired 24,193 shares through an RSU grant and 32,996 stock options. The company recently reported strong Q1 2026 financial results with a 38% increase in total revenue and earnings exceeding expectations, leading to a market capitalization of $1.06 billion.
Xeris Biopharma director Bormann-Kennedy sells $97,507 in stock By Investing.com
Barbara-Jean Anne Bormann-Kennedy, a director at Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), sold 16,000 shares of the company’s common stock for $97,507. This transaction, executed under a Rule 10b5-1 trading plan, occurred on June 4, 2026, with shares priced between $5.970 and $6.170. Concurrently, Ms. Bormann-Kennedy received restricted stock units and stock options, leading to a direct holding of 150,693 shares and 32,996 options.
Xeris Biopharma director Dawn Halkuff sells $121,885 in company stock
Xeris Biopharma director Dawn Halkuff sold 20,000 shares of company stock for $121,885 on June 4, 2026, as part of a Rule 10b5-1 trading plan. On the same day, she also acquired 24,193 shares through a restricted stock unit grant and received 32,996 stock options. These transactions come as InvestingPro analysis suggests the company is undervalued, and follow a strong first quarter for Xeris Biopharma, which saw a 38% revenue increase.
Xeris Biopharma director John Johnson sells $91,422 in shares
Xeris Biopharma director John Johnson sold 15,000 shares of the company's stock for $91,422 but also acquired 24,193 shares through an RSU grant and received 32,996 stock options. Following these transactions, Johnson increased his direct ownership of common stock. These events occur as Xeris Biopharma reported a 38% revenue increase for Q1 2026, exceeding EPS expectations despite slightly missing revenue forecasts.
